Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.Steven N. Seyedin, Nataliya Mar, Vadim S. Koshkin et al.|Journal of Clinical Oncology|2026Cited by 0
Clinical and genomic characteristics of advanced urothelial carcinoma (UC) patients (pts) who fail therapy with enfortumab vedodin (EV) plus pembrolizumab (P).Nataliya Mar, Steven N. Seyedin, Ali Raad et al.|Journal of Clinical Oncology|2026Cited by 0
Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).Mamta Parikh, Nataliya Mar, Suzanne M. Dufault et al.|Journal of Clinical Oncology|2026Cited by 0